Tumor-infiltrating endothelial cells and endothelial precursor cells in inflammatory breast cancer

被引:53
作者
Shirakawa, K
Shibuya, M
Heike, Y
Takashima, S
Watanabe, I
Konishi, F
Kasumi, F
Goldman, CK
Thomas, KA
Bett, A
Terada, M
Wakasugi, H
机构
[1] Natl Canc Ctr, Res Inst, Div Pharmacol, Chuo Ku, Tokyo 1040045, Japan
[2] Univ Tokyo, Inst Med Sci, Dept Genet, Tokyo, Japan
[3] Jichi Med Sch, Omiya Med Ctr, Dept Surg, Omiya, Saitama, Japan
[4] Japanese Fdn Canc Res, Dept Surg, Tokyo, Japan
[5] Watson Clin, Vasc Inst, Lakeland, FL USA
[6] Merck Res Labs, Dept Canc Res, W Point, PA USA
[7] Merck Res Labs, Dept Virus & Cell Biol, W Point, PA USA
[8] Natl Canc Ctr, Res Inst, Div Genet, Tokyo, Japan
[9] Natl Shikoku Canc Ctr, Dept Med Oncol & Clin Res, Shikoku, Ehime, Japan
关键词
inflammatory breast cancer; endothelial cell; endothelial precursor cell; VEGF; angiopoietin;
D O I
10.1002/ijc.10336
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Inflammatory breast cancer (IBC) is a specific type of breast tumor that generally has a poor prognosis, in spite of recent advances in treatment. In the present study, semi-quantitative reverse transcriptase polymerase chain reaction examination of resected specimens showed that angiogenic factors, not lymphangiogenic factors, are overexpressed in IBC tumors, compared with non-IBC tumors. Immunohistochemical analysis of the specimens revealed a significantly higher population of tumor-infiltrating (TI) endothelial cells (ECs) or endothelial precursor cells (EPCs) in tumor-associated stroma of IBC specimens than in non-IBC specimens. In a previous study, we examined the phenotype of host cells in response to transplanted IBC cells, using an established human IBC xenograft model (WIBC-9) (Shirakawa et al., Cancer Res 2001;61:445-51). The data obtained in that study are consistent with the findings of the present study. To explore the therapeutic potential of blocking vascular endothelial growth factor (VEGF) and angiopoietin (Ang) pathways in IBC, established vectors encoding soluble Flt-I (sFlt-I) and soluble Tie2 (sTie2) were injected directly into WIBC-9. Both vectors produced growth inhibition ratios of WIBC-9 that were significantly higher than those of a non-IBC xenograft (MC-5). Also, both vectors suppressed WIBC-9 lung metastases. The efficacy correlated with the number of TI ECs/EPCs, which was determined by fluorescence-activated cell sorting. These ECs/EPCs incorporated acetylated lipoprotein and were integrated within a HUVEC monolayer in vitro culture on day S. (C) 2002 Wiley-Liss, Inc.
引用
收藏
页码:344 / 351
页数:8
相关论文
共 22 条
[1]   AN EFFICIENT AND FLEXIBLE SYSTEM FOR CONSTRUCTION OF ADENOVIRUS VECTORS WITH INSERTIONS OR DELETIONS IN EARLY REGION-1 AND REGION-3 [J].
BETT, AJ ;
HADDARA, W ;
PREVEC, L ;
GRAHAM, FL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (19) :8802-8806
[2]   Inflammatory breast carcinoma: A community hospital experience [J].
Brooks, HL ;
Mandava, N ;
Pizzi, WF ;
Shah, S .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 1998, 186 (06) :622-629
[3]   Inflammatory breast carcinoma [J].
Chambler, AFW ;
Drew, PJ ;
Hill, ADK ;
Darzi, A ;
Monson, JRT .
SURGICAL ONCOLOGY-OXFORD, 1995, 4 (05) :245-254
[4]  
DINARELLO CA, 1991, BLOOD, V77, P1627
[5]   Clinical applications of angiogenic growth factors and their inhibitors [J].
Ferrara, N ;
Alitalo, K .
NATURE MEDICINE, 1999, 5 (12) :1359-1364
[6]   Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate [J].
Goldman, CK ;
Kendall, RL ;
Cabrera, G ;
Soroceanu, L ;
Heike, Y ;
Gillespie, GY ;
Siegal, GP ;
Mao, XZ ;
Bett, AJ ;
Huckle, WR ;
Thomas, KA ;
Curiel, DT .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) :8795-8800
[7]   Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF [J].
Holash, J ;
Maisonpierre, PC ;
Compton, D ;
Boland, P ;
Alexander, CR ;
Zagzag, D ;
Yancopoulos, GD ;
Wiegand, SJ .
SCIENCE, 1999, 284 (5422) :1994-1998
[8]   Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization [J].
Isner, JM ;
Asahara, T .
JOURNAL OF CLINICAL INVESTIGATION, 1999, 103 (09) :1231-1236
[9]  
Ito H, 1999, CANCER RES, V59, P5875
[10]   INHIBITION OF VASCULAR ENDOTHELIAL-CELL GROWTH-FACTOR ACTIVITY BY AN ENDOGENOUSLY ENCODED SOLUBLE RECEPTOR [J].
KENDALL, RL ;
THOMAS, KA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (22) :10705-10709